Cambrex Corp. has appointed Bruno Biscaro as president, Drug Products, with global responsibility for the company’s drug product business.

Mr. Biscaro has 30 years of experience in pharmaceutical leadership and joins Cambrex from Famar where he was president, North America. Prior to this role, he was President of Accucaps Industries and has also held numerous leadership positions for GlaxoSmithKline including his last mandate as Regional Director, Global Supply Network Program for the North American Supply Executive Team.

Also, Joe Nettleton has been appointed president, Drug Substance, with responsibility for operations at the Charles City, Iowa; Karlskoga, Sweden; Wiesbaden, Germany; and Tallinn, Estonia facilities. Mr. Nettleton previously served as vice president, US Operations and has been with Cambrex for 28 years.

Lastly, Simon Edwards has been appointed president, CDMO Sales & Marketing. He will provide customers with a single point of contact for the company’s CDMO services, as well as drive commercial activity and brand recognition for Cambrex as the leading small molecule company.

“I’m delighted to announce these appointments that underpin our strategy to be the leading small molecule company with the ability to serve customers across the entire drug lifecycle,” commented Shawn Cavanagh, executive vice president and chief operating officer. “Our recent acquisitions of Avista and Halo align with this strategy and leverages our core strengths, while positioning us as a leading global provider of end-to-end integrated services for small molecules. These appointments play a crucial role in Cambrex delivering a wider range of services to new and existing customers.”